The Effects of Divalent Cation-Chelated Prion Fibrils on the Immune Response of EOC 13.31 Microglia Cells.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101600052 Publication Model: Electronic Cited Medium: Internet ISSN: 2073-4409 (Electronic) Linking ISSN: 20734409 NLM ISO Abbreviation: Cells Subsets: MEDLINE

Original Publication: Basel, Switzerland : MDPI

Cations, Divalent/*pharmacology ; Chelating Agents/*pharmacology ; Microglia/*immunology ; Prions/*metabolism; Animals ; Cell Line ; Cytokines/metabolism ; Inflammation Mediators/metabolism ; Interleukin-1beta/genetics ; Interleukin-1beta/metabolism ; Mice ; Microglia/drug effects ; NF-KappaB Inhibitor alpha/genetics ; NF-KappaB Inhibitor alpha/metabolism ; NLR Family, Pyrin Domain-Containing 3 Protein/metabolism ; Peptides/chemistry ; Prions/chemistry ; RNA, Messenger/genetics ; RNA, Messenger/metabolism ; Reactive Oxygen Species/metabolism ; Repetitive Sequences, Amino Acid

Transmissible spongiform encephalopathies (TSEs) are epidemic neurodegenerative diseases caused by prion proteins; in particular, they are induced by misfolded prion proteins (PrP ^Sc ). PrP ^Sc tend to aggregate into insoluble amyloid prion fibrils (fPrP ^WT ), resulting in apoptosis of neuron cells and sequential neurodegeneration. Previous studies indicate that microglia cells play an important role in the innate immune system, and that these cells have good neuroprotection and delay the onset of TSEs. However, microglia can be a double-sided blade. For example, both Cu ²⁺ and Mn ²⁺ can induce microglia activation and secrete many inflammatory cytokines that are fatal to neuron cells. Unfortunately, PrP have cation binding sites at the N-terminus. When PrP ^Sc accumulate during microglial phagocytosis, microglia may change the phenotype to secrete pro-inflammation cytokines, which increases the severity of the disease. Some studies have revealed an increase in the concentration of Mn ²⁺ in the brains of patients. In this study, we treated microglia with fPrP ^WT and cations and determined IκBα and IL-1β expression by Western blotting and quantitative polymerase chain reaction. The results showed that Mn-fPrP ^WT decreased IκBα levels and dramatically increased IL-1β mRNA expression. In addition, competing binding between Cu ²⁺ and Mn ²⁺ can decrease the effect of Mn-fPrP ^WT on IκBα and IL-1β. The effects of divalent cations and fPrP ^WT in microglia inflammation are also discussed.

Continuum (Minneap Minn). 2015 Dec;21(6 Neuroinfectious Disease):1612-38. (PMID: 26633779)
Oxid Med Cell Longev. 2016;2016:2183026. (PMID: 27127546)
J Neural Transm Suppl. 2000;59:81-9. (PMID: 10961421)
Int J Mol Sci. 2021 Feb 11;22(4):. (PMID: 33670336)
Sci Adv. 2016 Jul 01;2(7):e1600014. (PMID: 27419232)
J Neurosci. 2001 Nov 1;21(21):8447-55. (PMID: 11606633)
J Neuroinflammation. 2014 Jun 03;11:98. (PMID: 24889886)
Lancet. 2006 Dec 9;368(9552):2061-7. (PMID: 17161728)
J Dermatol Sci. 2020 Jun;98(3):146-151. (PMID: 32173167)
Nat Med. 2015 Jul;21(7):677-87. (PMID: 26121197)
Viruses. 2013 Feb 11;5(2):654-62. (PMID: 23435237)
Nat Med. 2017 Sep 8;23(9):1018-1027. (PMID: 28886007)
Cell Mol Life Sci. 2012 Dec;69(24):4215-28. (PMID: 22926439)
Viruses. 2012 Dec;4(12):3389-419. (PMID: 23342365)
Br Med Bull. 2003;66:255-65. (PMID: 14522863)
J Mol Biol. 2005 Feb 18;346(2):645-59. (PMID: 15670611)
Prog Neurobiol. 2014 May;116:33-57. (PMID: 24440710)
Prion. 2015;9(6):420-8. (PMID: 26689487)
J Pathol. 2000 Mar;190(4):495-502. (PMID: 10700001)
Cell. 2010 Mar 19;140(6):821-32. (PMID: 20303873)
Biochem Soc Symp. 2004;(71):193-202. (PMID: 15777022)
Science. 2012 Jun 22;336(6088):1511-3. (PMID: 22723400)
Proc Natl Acad Sci U S A. 1998 Nov 10;95(23):13363-83. (PMID: 9811807)
Protein Sci. 2006 Mar;15(3):609-19. (PMID: 16452616)
Sci Signal. 2019 Jan 08;12(563):. (PMID: 30622196)
J Trace Elem Med Biol. 2017 Jan;39:50-53. (PMID: 27908423)
Antioxid Redox Signal. 2010 Jun 1;12(11):1271-94. (PMID: 19803746)
Mol Cell Neurosci. 2008 Mar;37(3):590-8. (PMID: 18234506)
Br Poult Sci. 1989 Mar;30(1):123-34. (PMID: 2743167)
Toxicol Sci. 2007 Aug;98(2):495-509. (PMID: 17483122)
J Neurol Neurosurg Psychiatry. 2004 Aug;75(8):1166-70. (PMID: 15258222)
Lancet. 2004 Feb 7;363(9407):417-21. (PMID: 14962520)
J Neurochem. 1999 Apr;72(4):1466-71. (PMID: 10098850)
Nat Neurosci. 2005 Jun;8(6):752-8. (PMID: 15895084)
J Neuroimmune Pharmacol. 2009 Dec;4(4):399-418. (PMID: 19655259)
BMC Pharmacol Toxicol. 2016 Nov 4;17(1):57. (PMID: 27814772)
Nat Rev Immunol. 2013 Dec;13(12):888-902. (PMID: 24189576)
CNS Neurol Disord Drug Targets. 2010 Apr;9(2):174-91. (PMID: 20205642)
Toxicol Lett. 2015 Jun 15;235(3):199-205. (PMID: 25929180)
Int J Mol Sci. 2013 Sep 03;14(9):17943-57. (PMID: 24005859)
Cell Death Dis. 2014 Jan 30;5:e1040. (PMID: 24481454)
Clin Lab Med. 2003 Mar;23(1):43-64. (PMID: 12733424)
Nat Commun. 2012;3:1134. (PMID: 23072804)
J Neurosci Res. 2004 Dec 1;78(5):723-31. (PMID: 15478178)
Trends Mol Med. 2011 Jan;17(1):14-24. (PMID: 20889378)
J Biol Chem. 2008 May 9;283(19):12831-9. (PMID: 18332141)

Keywords: NLRP3 inflammasome; inflammation; microglia; prion

0 (Cations, Divalent)
0 (Chelating Agents)
0 (Cytokines)
0 (Inflammation Mediators)
0 (Interleukin-1beta)
0 (NLR Family, Pyrin Domain-Containing 3 Protein)
0 (Nlrp3 protein, mouse)
0 (Peptides)
0 (Prions)
0 (RNA, Messenger)
0 (Reactive Oxygen Species)
139874-52-5 (NF-KappaB Inhibitor alpha)

Date Created: 20201017 Date Completed: 20210402 Latest Revision: 20240330

20240330

PMC7602007

10.3390/cells9102285

33066249